Drug intelligence / Profile preview

MC-002

Development stage: Phase 1
Modality: Small Molecules

Overview

MC-002 is an investigational agent that inhibits thromboxane A2, demonstrating positive effects on platelet aggregation and endothelial dysfunction. It was studied in preclinical research for its potential antithrombotic properties through thromboxane A2 pathway modulation.

Other names: (E) - 3 - (3 - methoxy - 4 - ((3, 5, 6 - trimethylpyrazin - 2 - yl) methoxy) phenyl) sodium acrylate

Targets

TYMP (Thymidine phosphorylase)

Beyond the preview

Go deeper on MC-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MC-002.

Explore the full profile